Salarius Pharmaceuticals (SLRX) Competitors $0.68 +0.01 (+0.79%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.68 0.00 (-0.15%) As of 04/17/2025 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SLRX vs. TCRT, DRMA, ADIL, SNGX, ONCO, KLTO, AEZS, AEON, ALBT, and CDTShould you be buying Salarius Pharmaceuticals stock or one of its competitors? The main competitors of Salarius Pharmaceuticals include Alaunos Therapeutics (TCRT), Dermata Therapeutics (DRMA), Adial Pharmaceuticals (ADIL), Soligenix (SNGX), Onconetix (ONCO), Klotho Neurosciences (KLTO), Aeterna Zentaris (AEZS), AEON Biopharma (AEON), Avalon GloboCare (ALBT), and Conduit Pharmaceuticals (CDT). These companies are all part of the "pharmaceutical products" industry. Salarius Pharmaceuticals vs. Alaunos Therapeutics Dermata Therapeutics Adial Pharmaceuticals Soligenix Onconetix Klotho Neurosciences Aeterna Zentaris AEON Biopharma Avalon GloboCare Conduit Pharmaceuticals Salarius Pharmaceuticals (NASDAQ:SLRX) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment, analyst recommendations and community ranking. Is SLRX or TCRT more profitable? Salarius Pharmaceuticals' return on equity of -140.28% beat Alaunos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Salarius PharmaceuticalsN/A -140.28% -105.76% Alaunos Therapeutics N/A -267.77%-209.18% Does the MarketBeat Community favor SLRX or TCRT? Salarius Pharmaceuticals received 19 more outperform votes than Alaunos Therapeutics when rated by MarketBeat users. However, 58.33% of users gave Alaunos Therapeutics an outperform vote while only 54.17% of users gave Salarius Pharmaceuticals an outperform vote. CompanyUnderperformOutperformSalarius PharmaceuticalsOutperform Votes2654.17% Underperform Votes2245.83% Alaunos TherapeuticsOutperform Votes758.33% Underperform Votes541.67% Does the media refer more to SLRX or TCRT? In the previous week, Salarius Pharmaceuticals had 3 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 3 mentions for Salarius Pharmaceuticals and 0 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 0.00 beat Salarius Pharmaceuticals' score of -0.14 indicating that Alaunos Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Salarius Pharmaceuticals Neutral Alaunos Therapeutics Neutral Which has higher valuation and earnings, SLRX or TCRT? Salarius Pharmaceuticals has higher earnings, but lower revenue than Alaunos Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSalarius PharmaceuticalsN/AN/A-$12.54M-$7.07-0.10Alaunos Therapeutics$10K397.05-$35.14MN/AN/A Do insiders and institutionals have more ownership in SLRX or TCRT? 11.9% of Salarius Pharmaceuticals shares are held by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are held by institutional investors. 1.4% of Salarius Pharmaceuticals shares are held by insiders. Comparatively, 5.1% of Alaunos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more volatility and risk, SLRX or TCRT? Salarius Pharmaceuticals has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Alaunos Therapeutics has a beta of -0.74, indicating that its stock price is 174% less volatile than the S&P 500. SummarySalarius Pharmaceuticals beats Alaunos Therapeutics on 6 of the 11 factors compared between the two stocks. Get Salarius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLRX vs. The Competition Export to ExcelMetricSalarius PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.17M$6.44B$5.30B$7.34BDividend YieldN/A3.21%5.45%4.30%P/E Ratio-0.086.8921.8617.80Price / SalesN/A230.51380.5997.73Price / CashN/A65.6738.2634.64Price / Book0.065.936.453.98Net Income-$12.54M$142.99M$3.22B$247.81M1 Month Performance-21.42%-13.57%-9.71%-7.84%1 Year Performance-82.78%-8.90%11.52%1.60% Salarius Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLRXSalarius Pharmaceuticals0.3125 of 5 stars$0.68+0.8%N/A-83.0%$1.17MN/A-0.0820Short Interest ↑News CoverageGap DownTCRTAlaunos Therapeutics0.6803 of 5 stars$3.00+1.7%N/A-79.8%$4.80M$10,000.000.0040Gap DownHigh Trading VolumeDRMADermata Therapeutics1.8927 of 5 stars$0.88-7.9%$6.00+578.7%-85.6%$4.80MN/A-0.058Short Interest ↑News CoverageGap DownADILAdial Pharmaceuticals2.3546 of 5 stars$0.72+13.7%$8.00+1,011.1%-68.4%$4.73MN/A-0.2220SNGXSoligenix1.4765 of 5 stars$1.87+1.6%N/A-69.8%$4.69M$840,000.00-0.2520Short Interest ↓ONCOOnconetix1.1121 of 5 stars$0.07flatN/A-98.9%$4.65M$1.87M0.0012Short Interest ↓Gap DownKLTOKlotho NeurosciencesN/A$0.16+6.2%N/AN/A$4.62MN/A0.00N/AGap DownAEZSAeterna ZentarisN/A$2.56-5.7%N/A-63.9%$4.59M$2.37M-0.1720Analyst ForecastNews CoverageGap DownAEONAEON Biopharma2.4773 of 5 stars$0.42-10.6%$360.00+86,313.8%-99.9%$4.39MN/A2.315Gap DownALBTAvalon GloboCare1.5232 of 5 stars$3.96+1.5%N/A-23.7%$4.33M$1.31M-0.205Upcoming EarningsGap UpCDTConduit Pharmaceuticals0.5131 of 5 stars$0.65+0.7%N/A-99.8%$4.33MN/A-0.023Gap Down Related Companies and Tools Related Companies TCRT Competitors DRMA Competitors ADIL Competitors SNGX Competitors ONCO Competitors KLTO Competitors AEZS Competitors AEON Competitors ALBT Competitors CDT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLRX) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Salarius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Salarius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
